Last reviewed: June 25, 2026 Last updated: June 25, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Pasha takes a personalized, physician-directed approach to help patients achieve meaningful progress with structure, accountability, and clinical oversight
These mechanisms are similar in principle to those of SGLT2 inhibitors (such as dapagliflozin and empagliflozin), the class of medications shown from 2020 onwards to slow CKD progression and reduce the risk of kidney failure
Even more concerning, some individuals experience: Gallbladder issues Pancreatitis Malnutrition from chronic nausea and reduced food intake Rebound weight gain if the medication is stopped And perhaps most problematic: semaglutide doesnt teach your body how to metabolize properlyit just suppresses hunger signals